乐心医疗 2026 年公告 关于控股子公司变更医疗器械注册证获得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"）控股子公司深圳市瑞 康宏业科技开发有限公司（以下简称"瑞康宏业"）近日接到广东省药品监督管 理局下发的《受理凭证》，获悉其申报的变更医疗器械注册证事项已获得受理， 现将相关情况公告如下： 上述数字式多道心电图机可通过体表电极采集来自成人和儿童病人静态下 的心电信号，记录的心电图能够帮助用户分析和诊断心脏疾病。数字式多道心电 图机的结构组成为：（1）型号为"e1200、e1200 plus、e1800、e1800 plus"的产 品由主机、心电采集盒、外购附件组成，外购附件包括电源适配器、心电导联线、 肢电极和胸电极；（2）型号为"e1201、e1201 plus、e1202、e1202 plus"的产品 由主机、外购附件组成，外购附件包括心电导联线、肢电极和胸电极。 心电工作站可通过体表电极采集来自成人和儿童病人静态下的心电信号，该 序号 产品名称 申请事项 受理号 分类 规格型号 主要变更 ...

Group 1 - The core point of the article is that 乐心医疗 (Lixun Medical) has reported its total number of shareholders as of February 13, 2026, which stands at 23,363 [1]

Group 1 - The core viewpoint of the news is that Lexin Medical (300562) has officially launched its large model application focused on cardiovascular and cerebrovascular disease risk assessment, with successful pilot results [1] - The company emphasizes that it cannot predict the specific impact of this business on future performance and advises investors to be cautious of risks [1] - This development reflects the company's innovative layout in the field of AI digital chronic disease management, which may positively influence market sentiment [1] Group 2 - In the recent stock performance, Lexin Medical's stock price showed noticeable fluctuations over the past seven trading days, closing at 14.65 yuan on February 13, a slight increase of 0.21% from 14.62 yuan on February 6 [2] - The stock experienced a volatility of 5.75% during this period, with a peak price of 15.03 yuan on February 11 [2] - In terms of capital flow, on February 11, there was a net outflow of 4.4588 million yuan from main funds, while speculative funds saw a net inflow of 4.9387 million yuan, indicating short-term capital divergence [2]

Group 1 - The core viewpoint of the article is that Lexin Medical is focusing on overseas markets for its business development in the next 1-2 years, aligning with its strategic direction and growth potential [2] - The company defines the second industry curve as related businesses that align with its strategic development direction and have greater growth potential [2] Group 2 - The company is currently positioning itself based on its strategic planning, indicating a clear focus on international expansion [2] - The response to investor inquiries highlights the company's commitment to its strategic goals and future business planning [2]

Core Viewpoint - The company has made progress in developing a large model application focused on cardiovascular diseases, which includes risk assessment capabilities and has undergone successful pilot testing [2] Group 1 - The large model application is primarily aimed at cardiovascular disease [2] - The application has been launched and has completed relevant pilot tests with positive results [2] - The company is unable to predict the future impact of this business on its performance [2]

Core Viewpoint - The company, Lexin Medical, has indicated that its smart ring product will not be launched in the consumer market before the Spring Festival due to ongoing software development and iteration processes [2] Group 1: Product Development - The software related to the smart ring is still under development and iteration [2] - The company will determine the launch timing based on internal business planning and external market conditions [2] - Specific details regarding the product launch will be announced in future communications [2]

Core Viewpoint - Le Xin Medical (300562.SZ) is focusing on digital chronic disease management solutions in European and American markets, offering products such as smart blood pressure monitors and smart blood glucose meters [2] Group 1 - The company's current business in Europe and the United States primarily revolves around Remote Patient Monitoring (RPM) solutions [2]

Core Viewpoint - Lexin Medical (300562.SZ) is focusing on developing a multi-dimensional physiological monitoring product line that enables high-precision data collection and transmission [1] Group 1: Product Development - The company has developed a large model application in the vertical field of cardiovascular diseases [1] - Lexin Medical plans to integrate this application with its medical-grade health monitoring products [1] Group 2: Service Offering - The company aims to provide a comprehensive chronic disease management solution that includes "medical-grade smart monitoring devices + data analysis + medical health services" [1] Group 3: Future Performance - The company is currently unable to predict the impact of these related businesses on its future performance [1]

Core Viewpoint - The aging population is driving the growth of the silver economy, and the company aims to leverage its product matrix to provide comprehensive health monitoring for the elderly [1] Group 1: Company Strategy - The company currently offers a range of health monitoring products, including blood pressure, blood sugar, body fat, and heart rate monitoring for the elderly [1] - The company plans to actively seek relevant partnerships to capitalize on its existing business advantages and explore new emerging cooperation models [1] Group 2: Market Outlook - The company is unable to predict the impact of future business developments, indicating uncertainty in the market environment [1]

Group 1 - The core viewpoint of the article highlights that despite the significant contribution of overseas markets to the company's revenue and rapid profit growth, the stock price of the company has remained stagnant for several years [1] - The company acknowledges the impact of macroeconomic factors and market sentiment on its stock price performance, indicating that it is committed to improving operational management and enhancing communication with the market to better convey its investment value [1] - The company has achieved steady profit growth through strategic upgrades and optimization of its business structure, reflecting its efforts to adapt and thrive in the competitive medical industry [1]